Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Consensus Price Target from Analysts

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) have been given an average rating of “Buy” by the six analysts that are currently covering the company, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have covered the stock in the last year is $23.67.

A number of research firms have recently weighed in on ACRV. HC Wainwright restated a “buy” rating and issued a $22.00 target price on shares of Acrivon Therapeutics in a report on Thursday, November 14th. JMP Securities reaffirmed a “market outperform” rating and issued a $17.00 price objective on shares of Acrivon Therapeutics in a research note on Monday, September 16th. Piper Sandler Companies reissued a “buy” rating and set a $30.00 target price on shares of Acrivon Therapeutics in a research report on Friday, September 6th. BMO Capital Markets lowered their price target on Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating for the company in a research report on Thursday, November 14th. Finally, LADENBURG THALM/SH SH upgraded shares of Acrivon Therapeutics from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a research report on Monday, September 16th.

Acrivon Therapeutics Price Performance

NASDAQ:ACRV opened at $6.42 on Friday. The company has a market cap of $199.92 million, a price-to-earnings ratio of -2.38 and a beta of 0.55. Acrivon Therapeutics has a 1 year low of $3.19 and a 1 year high of $11.90. The stock’s 50 day simple moving average is $7.48 and its two-hundred day simple moving average is $7.61.

Institutional Trading of Acrivon Therapeutics

Large investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in Acrivon Therapeutics by 6.6% during the 1st quarter. Vanguard Group Inc. now owns 507,185 shares of the company’s stock valued at $3,626,000 after purchasing an additional 31,208 shares in the last quarter. American International Group Inc. grew its holdings in Acrivon Therapeutics by 39.2% during the 1st quarter. American International Group Inc. now owns 6,016 shares of the company’s stock worth $43,000 after acquiring an additional 1,695 shares in the last quarter. Bank of New York Mellon Corp increased its position in Acrivon Therapeutics by 50.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 36,632 shares of the company’s stock valued at $212,000 after purchasing an additional 12,219 shares during the period. Rhumbline Advisers raised its holdings in shares of Acrivon Therapeutics by 48.9% in the 2nd quarter. Rhumbline Advisers now owns 16,209 shares of the company’s stock valued at $94,000 after purchasing an additional 5,320 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in shares of Acrivon Therapeutics during the second quarter valued at approximately $58,000. Hedge funds and other institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.